Jagsonpal Pharmaceuticals Q1 Results Revenue Up 10.81% QoQ and 2.14% YoY

Jagsonpal Pharmaceuticals Growth Comparison 

Jagsonpal Pharmaceuticals Q1 Results: In the first quarter of the fiscal year 2024 (June 2024), Jagsonpal Pharmaceuticals reported a total revenue of ₹61.44 crores. This is a significant increase of 10.81% from the previous quarter (March 2023) when the revenue was ₹55.45 crores. Compared to the same quarter last year (June 2023), the revenue grew by 2.14%, from ₹60.15 crores.

Jagsonpal Pharmaceuticals expenses for selling, general, and administrative costs were ₹14.74 crores, up by 11.58% from ₹13.21 crores in the previous quarter. Compared to the same period last year, these expenses increased by 7.58%.

Jagsonpal Pharmaceuticals Depreciation and amortization expenses surged to ₹1.07 crores, which is a 122.92% increase from ₹0.48 crores in the last quarter and a 172.77% rise from ₹0.39 crores a year ago.

Jagsonpal Pharmaceuticals Other operating expenses also rose to ₹11.73 crores, up by 23.85% from ₹9.47 crores last quarter and 3.62% from ₹11.32 crores last year.

Jagsonpal Pharmaceuticals total operating expenses were ₹55.56 crores, showing a 9.48% increase from the previous quarter and 7.03% from the same quarter last year. Despite higher revenue, the operating income dropped to ₹5.88 crores, a 25.21% increase from the previous quarter but a 28.66% decrease from a year ago.

Jagsonpal Pharmaceuticals’ Net income before taxes was ₹7.11 crores, down by 2.87% from the last quarter and 29.54% from last year. The net income was ₹5.33 crores, a decrease of 4.82% from the previous quarter and 28.75% from last year.

The diluted normalized earnings per share (EPS) were ₹2.82, a 27.03% increase from ₹2.22 in the last quarter but a slight decrease of 0.99% from ₹2.85 a year ago.

Here's a summary of Jagsonpal Pharmaceuticals' Q1 results:

(Rs. in Crores)

Source: Here 

For More Q1 Results check our Twitter Page

Visit our website for more Q1 results

Jagsonpal Pharmaceuticals Q1 Results 

The financial results for Jagsonpal Pharmaceuticals for the quarter ending on June 30, 2024, show how the company performed in that period. The company earned Rs. 614.39 million from its main business activities and another Rs. 14.44 million from other sources, making a total income of Rs. 628.83 million for the quarter. This total income is slightly higher compared to the same quarter last year and also up from the previous quarter.

Jagsonpal Pharmaceuticals’ expenses, we see several costs. The company spent Rs. 43.87 million on materials and Rs. 200.34 million on buying stock. There were also changes in the value of their stock, with a reduction of Rs. 21.17 million. Other major expenses included Rs. 147.39 million for employee salaries and Rs. 24.25 million for share-based payments. Overall, the total expenses were Rs. 524.88 million, which is a bit more than the previous quarter but close to last year’s figure.

After covering all expenses, Jagsonpal Pharmaceuticals had a profit of Rs. 103.95 million before accounting for taxes. After paying taxes, the net profit was Rs. 53.29 million. The company also reported a total comprehensive income of Rs. 52.81 million. Earnings per share were Rs. 1.94, and the company’s total reserves, excluding any revaluation reserves, were Rs. 1,821.96 million.

Here is a summary of the unaudited financial results for Jagsonpal Pharmaceuticals for the quarter ended 30 June 2024:

(Rs. in Million)

Jagsonpal Pharmaceuticals Financial Metrics

Jagsonpal Pharmaceuticals has a market capitalization of ₹1,058 crore, indicating its total value in the stock market. The current stock price is ₹400, with a high of ₹475 and a low of ₹270 over a period. The stock's Price-to-Earnings (P/E) ratio is 46.5, which shows how much investors are willing to pay for each unit of earnings. The book value per share is ₹70.9, representing the company's net asset value per share. The dividend yield is 1.21%, meaning shareholders receive this percentage of the stock price in dividends.

Here's a summary of the financial metrics:

Quarterly Results 

For Jagsonpal Pharmaceuticals, the financial data for December 2023, March 2024, and June 2024 shows various trends. In December 2023, the company had sales of Rs. 47.23 crores and expenses of Rs. 43.83 crores, resulting in an operating profit of Rs. 3.40 crores and a profit before tax of Rs. 5.28 crores. The net profit was Rs. 3.96 crores with an EPS of Rs. 1.51. In March 2024, sales fell to Rs. 43.49 crores, and expenses decreased to Rs. 40.82 crores. Operating profit dropped to Rs. 2.67 crores, leading to a profit before tax of Rs. 4.54 crores and a net profit of Rs. 3.55 crores.

Here's the data for Dec 2023, Mar 2024, and Jun 2024:

About Jagsonpal Pharmaceuticals 

Jagsonpal Pharmaceuticals is a company based in India that focuses on making affordable and high-quality healthcare products. Founded over fifty years ago, Jagsonpal is known for its strong values of safety, responsibility, trust, and integrity. These values guide their work and partnerships. The company aims to build a global brand and is proud of its journey towards self-reliance.

Jagsonpal values its employees, who are key to its success. The company continues to innovate and create value in the healthcare industry, staying committed to its mission of providing effective healthcare solutions worldwide.